BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 7532507)

  • 1. Antibody-induced modulation and intracellular transport of CD10 and CD19 antigens in human malignant B cells.
    Pulczynski S
    Leuk Lymphoma; 1994 Oct; 15(3-4):243-52. PubMed ID: 7532507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-induced modulation and intracellular transport of CD10 and CD19 antigens in human B-cell lines: an immunofluorescence and immunoelectron microscopy study.
    Pulczynski S; Boesen AM; Jensen OM
    Blood; 1993 Mar; 81(6):1549-57. PubMed ID: 7680920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation and intracellular transport of CD20 and CD21 antigens induced by B1 and B2 monoclonal antibodies in RAJI and JOK-1 cells--an immunofluorescence and immunoelectron microscopy study.
    Pulczynski S; Boesen AM; Jensen OM
    Leuk Res; 1994 Jul; 18(7):541-52. PubMed ID: 7517481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Killing of autologous B-lineage malignancy using CD3 x CD19 bispecific monoclonal antibody in end stage leukemia and lymphoma.
    Haagen IA; Geerars AJ; de Lau WB; Clark MR; van de Griend RJ; Bast BJ; de Gast BC
    Blood; 1994 Jul; 84(2):556-63. PubMed ID: 7517719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Killing of human leukaemia/lymphoma B cells by activated cytotoxic T lymphocytes in the presence of a bispecific monoclonal antibody (alpha CD3/alpha CD19).
    Haagen IA; van de Griend R; Clark M; Geerars A; Bast B; de Gast B
    Clin Exp Immunol; 1992 Dec; 90(3):368-75. PubMed ID: 1281055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fc gamma receptor II (CD32) on malignant B cells influences modulation induced by anti-CD19 monoclonal antibody.
    Vervoordeldonk SF; Merle PA; van Leeuwen EF; van der Schoot CE; von dem Borne AE; Slaper-Cortenbach IC
    Blood; 1994 Mar; 83(6):1632-9. PubMed ID: 7510146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The CD24 antigen discriminates between pre-B and B cells in human bone marrow.
    Duperray C; Boiron JM; Boucheix C; Cantaloube JF; Lavabre-Bertrand T; Attal M; Brochier J; Maraninchi D; Bataille R; Klein B
    J Immunol; 1990 Dec; 145(11):3678-83. PubMed ID: 1700990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins.
    Uckun FM; Jaszcz W; Ambrus JL; Fauci AS; Gajl-Peczalska K; Song CW; Wick MR; Myers DE; Waddick K; Ledbetter JA
    Blood; 1988 Jan; 71(1):13-29. PubMed ID: 3257143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo.
    Ward E; Mittereder N; Kuta E; Sims GP; Bowen MA; Dall'Acqua W; Tedder T; Kiener P; Coyle AJ; Wu H; Jallal B; Herbst R
    Br J Haematol; 2011 Nov; 155(4):426-37. PubMed ID: 21902688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy.
    Haagen IA
    Leuk Lymphoma; 1995 Nov; 19(5-6):381-93. PubMed ID: 8590837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibodies are capable of directing superantigen-mediated T cell killing of chronic B lymphocytic leukemia cells.
    Gidlöf C; Dohlsten M; Kalland T; Tötterman TH
    Leukemia; 1995 Sep; 9(9):1534-42. PubMed ID: 7544852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human Lyb-2 homolog CD72 is a marker for progenitor B-cell leukemias.
    Schwarting R; Castello R; Moldenhauer G; Pezzutto A; von Hoegen I; Ludwig WD; Parnes JR; Dörken B
    Am J Hematol; 1992 Nov; 41(3):151-8. PubMed ID: 1384316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against BCL-1 murine B-cell leukemia.
    Uckun FM; Chelstrom LM; Irvin JD; Finnegan D; Gunther R; Young J; Kuebelbeck V; Myers DE; Houston LL
    Blood; 1992 May; 79(10):2649-61. PubMed ID: 1375109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies.
    Bohlen H; Manzke O; Patel B; Moldenhauer G; Dörken B; von Fliedner V; Diehl V; Tesch H
    Cancer Res; 1993 Sep; 53(18):4310-4. PubMed ID: 7689932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies.
    Press OW; Farr AG; Borroz KI; Anderson SK; Martin PJ
    Cancer Res; 1989 Sep; 49(17):4906-12. PubMed ID: 2667754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Constitutive endocytosis and degradation of CD22 by human B cells.
    Shan D; Press OW
    J Immunol; 1995 May; 154(9):4466-75. PubMed ID: 7722303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo antitumor activity of a chimeric anti-CD19 antibody.
    Pietersz GA; Wenjun L; Sutton VR; Burgess J; McKenzie IF; Zola H; Trapani JA
    Cancer Immunol Immunother; 1995 Jul; 41(1):53-60. PubMed ID: 7543822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B cell antigen receptor-mediated apoptosis. Importance of accessory molecules CD19 and CD22, and of surface IgM cross-linking.
    Chaouchi N; Vazquez A; Galanaud P; Leprince C
    J Immunol; 1995 Apr; 154(7):3096-104. PubMed ID: 7534787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AFTR: a fifth human B-cell-specific surface antigen.
    Pesando JM; Stucki MA
    Hum Immunol; 1990 Mar; 27(3):193-207. PubMed ID: 2341301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does CD34+ cell selection enrich malignant stem cells in B cell (and other) malignancies?
    Reading CL
    J Hematother; 1996 Apr; 5(2):97-8. PubMed ID: 8723783
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.